E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
Spinal Muscular Atrophy (SMA) |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Musculoskeletal Diseases [C05] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10041582 |
E.1.2 | Term | Spinal muscular atrophy |
E.1.2 | System Organ Class | 10010331 - Congenital, familial and genetic disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this study is to evaluate the clinical outcomes following treatment with nusinersen in participants with spinal muscular atrophy (SMA) who previously received onasemnogene abeparvovec. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives of this study are to evaluate the safety and tolerability; clinical outcomes and pharmacodynamics (PD) of nusinersen treatment in participants with SMA who previously received onasemnogene abeparvovec. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Key Inclusion Criteria: - Genetic documentation of 5q SMA homozygous gene survival motor neuron 1 (SMN1) deletion or mutation, or compound heterozygous mutation - SMN2 copy number of ≥ 1 - ≤ 36 months of age at the time of first nusinersen dose - Must have previously received onasemnogene abeparvovec per the approved label or local/regional regulations ≥ 2 months prior to first nusinersen dose - Must have suboptimal clinical status per the Investigator For Subgroups A and B: - < 300 days of age at the time of first nusinersen dose - SMN2 copy number of 2 For Subgroup A: - SMA symptom onset ≤ 4 months (120 days) of age - Must have received intravenous (IV) onasemnogene abeparvovec at >6 weeks to ≤ 6 months (43 days to 180 days) of age - Must have received IV onasemnogene abeparvovec after SMA symptom onset For Subgroup B: - Must have received IV onasemnogene abeparvovec at ≤ 6 weeks (42 days) of age
Note: other protocol defined Inclusion/Exclusion criteria may apply. |
|
E.4 | Principal exclusion criteria |
Key Exclusion Criteria: - Prior exposure to nusinersen - Ongoing severe or serious AEs related to onasemnogene abeparvovec - Treatment with an investigational drug, biological agent, or device within 30 days or 5 half-lives of the agent, whichever is longer, prior to study; any prior or current treatment with any survival motor neuron 2 (SMN2)-directed splicing modifier; prior antisense oligonucleotide treatment or cell transplantation; gene therapy for the treatment of SMA other than onasemnogene abeparvovec. Note: treatment with onasemnogene abeparvovec as part of an investigational study is allowed For Subgroups A and B: - Weight-for-age is below the third percentile, based on WHO Child Growth Standards at the time of receiving onasemnogene abeparvovec. Adjustments for the gestational weight of premature babies enrolled in Subgroups A and B are allowed provided IV onasemnogene abeparvovec was dosed per the approved label or per local/regional regulations.
Note: other protocol defined Inclusion/Exclusion criteria may apply. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Total Hammersmith Infant Neurological Examination (HINE) Section 2 Motor Milestones Score
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
1) Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) 2) Number of Participants with Change from Baseline in Clinical Laboratory Parameters 3) Number of Participants with Change from Baseline in Electrocardiograms (ECGs) 4) Number of Participants with Change from Baseline in Vital Signs 5) Number of Participants who Achieved Motor Milestones as Assessed by World Health Organization (WHO) Criteria 6) Change from Baseline in Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) Score 7) Change from Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) Score 8) Change from Baseline in Revised Upper Limb Module (RULM) Score 9) Time to Death or Permanent Ventilation 10) Change from Baseline in Cerebrospinal Fluid (CSF) levels of Neurofilament Light Subunit (NF-L) 11) Change from Baseline in Plasma levels of NF-L |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
For Items 1-9 and 11 up to day 778; for item 10 up to day 659 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| Information not present in EudraCT |
E.8.4 | The trial involves multiple sites in the Member State concerned | Information not present in EudraCT |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 6 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Israel |
Japan |
United States |
Germany |
Italy |
Spain |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 4 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 4 |
E.8.9.2 | In all countries concerned by the trial months | 9 |